Costs and benefits of bevacizumab vial sharing for the treatment of retinal diseases.

Publisher: BioMed Central Country of Publication: England NLM ID: 100968562 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2458 (Electronic) Linking ISSN: 14712458 NLM ISO Abbreviation: BMC Public Health Subsets: MEDLINE

Original Publication: London : BioMed Central, [2001-

Drug Costs*; Angiogenesis Inhibitors/*economics ; Bevacizumab/*economics ; Retinal Diseases/*drug therapy ; Retinal Diseases/*economics; Aged ; Angiogenesis Inhibitors/therapeutic use ; Bevacizumab/therapeutic use ; Brazil ; Cost-Benefit Analysis ; Female ; Health Care Costs ; Humans ; Intravitreal Injections/economics ; Middle Aged ; Retrospective Studies

Background: Antiangiogenic therapy has proved to be an important therapeutic tool for many retinal vascular diseases; however, its availability is limited in developing countries. This study sought to describe the bevacizumab vial sharing process and to evaluate the impact of this repackaging system on the costs incurred in a Brazilian public hospital.
Method: This retrospective study compared the number and costs of intravitreal antiangiogenic injections approved via court order in the first year of the study (2015) to the number and costs of the bevacizumab injections provided through the use of vial sharing in the second year of the study (2016). Vial sharing consists of the traditional process used to repackage bevacizumab; in this case, however, the drug samples used were the residual volume from the preparation of bevacizumab for oncology patients. The hospital adhered to the guidelines established by the Brazilian Health Surveillance Agency (ANVISA).
Results: In the first year of the study and using medication obtained through court orders, 550 intravitreal injections were performed in the ophthalmology ambulatory care center. Based on local pricing tables, the total cost of the medication was BRL$1,036,056.25 (USD$267,546.58), and the average cost of each application was BRL$1883.74 (USD$486.45). In the second year of the study, 1081 intravitreal applications were performed at the same hospital using doses obtained through bevacizumab vial sharing. The total cost was BRL$21,942.49 (USD$5663.30) and the per-unit cost was BRL$20.30, or USD$5.23 (a savings of 97.88%).
Conclusion: This study found that bevacizumab vial sharing led to a significant reduction in public health care costs associated with antiangiogenic treatment and increased the availability of the drug to public health care patients. These results can be extrapolated to other types of drugs and health care systems.

N Engl J Med. 2000 Feb 17;342(7):483-92. (PMID: 10675430)
Diabetes Care. 2004 May;27(5):1047-53. (PMID: 15111519)
Br J Ophthalmol. 2007 Sep;91(9):1244-6. (PMID: 17431015)
J Ocul Pharmacol Ther. 2009 Feb;25(1):65-9. (PMID: 19232008)
Cad Saude Publica. 2009 Dec;25(12):2543-52. (PMID: 20191146)
N Engl J Med. 2011 May 19;364(20):1897-908. (PMID: 21526923)
BMJ. 2013 Mar 25;346:f1049. (PMID: 23529982)
Br J Ophthalmol. 2015 Jul;99(7):954-9. (PMID: 25631483)
BMC Ophthalmol. 2015 Jul 07;15:71. (PMID: 26149170)
Health Technol Assess. 2015 Oct;19(78):1-298. (PMID: 26445075)
Ophthalmology. 2016 Jan;123(1):70-77.e1. (PMID: 26477843)
JAMA Ophthalmol. 2016 Jan;134(1):95-9. (PMID: 26512939)
Oncotarget. 2016 Apr 19;7(16):21247-58. (PMID: 26789111)
BMJ. 2016 Feb 29;352:i788. (PMID: 26932932)
JAMA Ophthalmol. 2016 Aug 1;134(8):888-96. (PMID: 27280850)
Curr Opin Ophthalmol. 2017 Nov;28(6):636-643. (PMID: 28837425)
Rev Assoc Med Bras (1992). 1994 Jul-Sep;40(3):186-8. (PMID: 7787869)
Invest Ophthalmol Vis Sci. 1995 Jan;36(1):182-91. (PMID: 7822146)
Ophthalmology. 1995 Jan;102(1):7-16. (PMID: 7831044)

Keywords: Anti-vascular endothelial growth factor; Bevacizumab; Brazil; Public hospitals; Repackaging; Vial sharing

0 (Angiogenesis Inhibitors)
2S9ZZM9Q9V (Bevacizumab)

Date Created: 20190913 Date Completed: 20191218 Latest Revision: 20200225

20221213

PMC6740002

10.1186/s12889-019-7562-y

31510981